163. Clin Cancer Res. 2018 Jul 1;24(13):2981-2983. doi: 10.1158/1078-0432.CCR-18-0463.Epub 2018 Apr 23.Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.Spring L(1), Bardia A(2).Author information: (1)Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.(2)Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. Bardia.Aditya@mgh.harvard.edu.Ribociclib is an orally active, highly selective inhibitor of cyclin-dependentkinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormonereceptor-positive breast cancer. The addition of ribociclib to an aromataseinhibitor has resulted in marked improvements in progression-free survival forpatients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981-3. ©2018AACRSee related article by Shah et al., p. 2999.©2018 American Association for Cancer Research.DOI: 10.1158/1078-0432.CCR-18-0463 PMID: 29685881 